Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today announced the availability of Transcranial…
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…
HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final…